Rebound insomnia and newer hypnotics.
Level 5 - mechanism / opinion, no new human data
Narrative review of literature without systematic review methodology
PubMed 1523276 · doi:10.1007/BF02245108
What was done
The author reviewed evidence on rebound insomnia following hypnotic discontinuation, specifically evaluating newer selective benzodiazepine receptor agonists (quazepam, zolpidem) and atypical agents (zopiclone) against older benzodiazepines, and discussed methodological needs such as sleep-laboratory and night-by-night clinical analyses.
What was found
The abstract reports no quantitative data or specific numerical values. It qualitatively notes that available evidence, while limited, is consistent with claims of lower rebound potential for newer agents compared with older benzodiazepine hypnotics of equivalent duration of action.
Why it matters
It contextualizes early evidence regarding whether newer, subtype-selective hypnotic agents reduce the risk of post-discontinuation sleep worsening seen with conventional benzodiazepines.
Limits
The abstract reports no sample sizes, effect sizes, or study counts. Findings are drawn from a non-systematic narrative review of limited early evidence, and the author explicitly notes that further rigorous studies are required before conclusions can be fully accepted.
Cited by
- supports Discontinuing sleeping pills leads to rebound insomnia, causing patients to return to sleep quality that is as bad as or worse than before starting medication.